Union minister Prakash Javadekar on Friday accused the Punjab govt of selling Covaxin doses to private hospitals at a profit
Lucknow: Bahujan Samaj Party (BSP) chief Mayawati on Saturday hit out at the Congress-led Punjab government for allegedly selling COVID-19 vaccine doses procured under the state quota to private hospitals at a higher rate, saying profiteering during an emergency is “indecent and inhuman”.
Her remarks came a day after the Punjab government asked private hospitals to return all vaccine stock meant for the 18-44 age group and ordered a probe into the allegations.
The recalled vaccine doses will be administered free to this age group by the government, state Health Minister Balbir Singh Sidhu said.
In a tweet in Hindi, Mayawati said, “The Congress government of Punjab is buying COVID-19 vaccines at Rs 400 (each) from the Centre and selling them to private hospitals at Rs 1,060 instead of passing on the benefits to the people through government hospitals. Profiteering during an emergency is indecent, inhuman, condemnable and extremely saddening.”
1. पंजाब की कांग्रेस सरकार द्वारा कोरोना वैक्सीन को केन्द्र से 400 रुपए में खरीद कर उसे सरकारी अस्पतालों के ज़रिए जनता को उसका लाभ देने के बजाय उसे प्राइवेट अस्पतालों को 1,060 रुपए में बेचकर आपदा में भी मुनाफा कमाने का कृत्य अशोभनीय, अमानवीय, निन्दनीय व अति-दुर्भाग्यपूर्ण। 1/2
— Mayawati (@Mayawati) June 5, 2021
“This makes it clear that the Congress’ stand and statements on vaccines so far lacked seriousness. The BSP demands that the Centre take cognisance of this,” she said.
Referring to media reports, Union Minister and senior BJP leader Prakash Javadekar had on Friday alleged the Punjab government got over 1.40 lakh doses of Covaxin at Rs 400 each and gave some of them to 20 private hospitals at Rs 1,000 each.
This is “dangerous” news, he had said.
The Centre has also written to the Punjab government seeking a clarification over reports that it sold Covaxin to private hospitals and earned a profit.
The Insidexpress is now on Telegram and Google News. Join us on Telegram and Google News, and stay updated.